UNH

UnitedHealth GroupC

NYSE / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$470.00

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$400.00

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$330.00

Analysis reference price unavailable

Analysis 2026-10-16 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-16

AI commentary

The initial October 13 close was $377.76, down 0.2% on the day; shares then closed at $395.62 on October 14 and $406.67 on October 15, about 7.4% above the pre-release October 12 close. The rebound occurred alongside broader healthcare buying, so it should not be attributed solely to earnings. Post-print target revisions were mixed, and a dependable aggregate estimate-revision series is unavailable. Social, options, short-interest and employee readings were not supplied; zero sentiment fields denote unavailable data, not neutral readings. https://chartexchange.com/symbol/nyse-unh/historical/ https://www.benzinga.com/quote/UNH/price-targets

RankAlpha Sentiment Codex - 2026-10-16

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Impact

tentative

Confidence

AI events

2026-10-13eventQ3 beat and higher 2026 outlook face post-print scrutinyMedium impact

On October 13, UnitedHealth reported $112.7 billion of revenue, $4.69 adjusted EPS and an 88.4% medical care ratio, and raised its 2026 adjusted EPS outlook to at least $20.50 from $19.50–$20.00. The medical care ratio included $610 million of favorable prior-period reserve development, making underlying cost control important to the earnings interpretation. [#8-K-2026-10-13] [#SEC-8K-2026-10-13] https://www.sec.gov/Archives/edgar/data/731766/000073176626000255/earningsrelease3q26unh.htm

2027-01-01catalyst2027 Medicare plan-year economicsMedium impact

The 2027 Medicare plan rollout will test whether benefit and pricing changes preserve membership while improving margins. January 1 is the plan-year start, not an announced financial-results date; enrollment and margin outcomes remain unproven. [#PR-2026-10-01] https://www.unitedhealthgroup.com/newsroom/2026/2026-10-01-uhc-2027-medicare-plans-focus-on-affordability-simplicity.html

2027-01-31catalystSustainability of medical-cost and cash-flow improvementMedium impact

Q3 operating cash flow was $5.1 billion, or 1.2 times net income, versus $11.1 billion and 1.9 times net income in Q2. Future results need to substantiate the raised outlook without relying on favorable reserve development. The date is an assessment horizon, not a confirmed reporting date. [#SEC-8K-2026-10-13] [#SEC-8K-2026-07-16] https://www.sec.gov/Archives/edgar/data/731766/000073176626000255/earningsrelease3q26unh.htm

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-16 • Updated nightlySource: Internal modelMethodology